The others (136 out of 151) are indicative of aberrantly high Kras activity by either containing constitutively active mu-Kras, or showing Kras mRNA upregulation, which is consistent with the Kras hyperactivity in the vast majority of pancreatic adenocarcinomas. This evidence concerns the gene KRAS and pancreatic adenocarcinoma.